Please complete the form here or contact [email protected] to learn more about licensing content from the Endocrine Society.

If you believe you should have access to this media, please login.

Survodutide: A Novel GCGR/GLP-1R Dual Agonist in Development for People Living with Overweight/Obesity and those with MASH

Presentations in This Video

Introduction to the development of incretin therapy

Richard D DiMarchi, PhD

Indiana University

GCGR/GLP1-R dual agonist survodutide

Alessandra -- Lafranconi, Dr Dr

Boehringer Ingelheim

Chair

Carlos -- Bernal-Mizrachi, MD

WASHINGTON UNIVERSITY

Related Media